IGC Pharma reports Q2 2026 results; CALMA enrollment nears closure
IGC Pharma reports Q2 2026 results and says its CALMA Alzheimer’s trial moves within six randomizations of enrollment closure.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.